BRIEF published on 11/22/2024 at 18:05, 14 hours 53 minutes ago MedinCell: Update of share capital and voting rights Share Capital Voting Rights Euronext Actions Medincell
BRIEF published on 11/22/2024 at 18:05, 14 hours 53 minutes ago MedinCell : Mise à jour du capital social et des droits de vote Droits De Vote Euronext Capital Social Actions Medincell
PRESS RELEASE published on 11/22/2024 at 18:00, 14 hours 58 minutes ago Informations privilégiées / Autres communiqués Euronext informe sur les droits de vote et le capital social de MedinCell. MedinCell, biopharmaceutique en France, développe des médicaments injectables à action prolongée Droits De Vote Euronext Capital Social Biopharmaceutique Medincell
BRIEF published on 11/06/2024 at 13:47, 16 days 19 hours ago Medincell: 2024 revenues on the rise and significant clinical progress Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
BRIEF published on 11/06/2024 at 13:47, 16 days 19 hours ago Medincell : Revenus 2024 à la hausse et avancée clinique significative Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 16 days 19 hours ago Informations privilégiées / Autres communiqués Medincell relève ses prévisions de revenus UZEDY® de 25% et franchit une étape majeure dans l'essai clinique de l'Olanzapine LAI. Tous les détails dans le communiqué de presse de Teva pour le troisième trimestre 2024 Revenus Essai Clinique Medincell Teva UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 16 days 19 hours ago Inside Information / Other news releases Medincell achieves 25% increase in 2024 UZEDY® revenue outlook reaching $100M and key milestone in Olanzapine LAI Phase 3 clinical trials. Teva Pharmaceuticals shares Q3 results Revenue Clinical Trials Medincell Teva Pharmaceuticals UZEDY
BRIEF published on 10/01/2024 at 15:47, 1 month 21 days ago Franchissement de seuil par Mirova dans MEDINCELL Capital Franchissement De Seuil Actions Medincell Mirova
BRIEF published on 10/01/2024 at 15:47, 1 month 21 days ago Threshold crossing by Mirova in MEDINCELL Capital Actions Threshold Crossing Medincell Mirova
PRESS RELEASE published on 10/01/2024 at 15:42, 1 month 21 days ago Franchissement de seuil Déclaration de franchissement de seuil par Mirova pour le compte de fonds gérés, détenant 7,07% du capital et 5,01% des droits de vote de MEDINCELL Acquisition Franchissement De Seuil AMF Medincell Mirova
Published on 11/22/2024 at 23:55, 9 hours 3 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 28 minutes ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 9 hours 53 minutes ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 28 minutes ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 14 hours 44 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 15 hours 5 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 3 minutes ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 16 hours 58 minutes ago Proposed cancellation of admission to trading
Published on 11/22/2024 at 16:15, 16 hours 43 minutes ago NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/21/2024 at 06:58, 2 days 2 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
